PHARMARON(300759) 每日经济新闻·2025-03-26 14:30Core Insights - The company reported a revenue of 12.276 billion yuan for 2024, marking a growth of 6.39% year-on-year, with net profit reaching 1.793 billion yuan, up 12.01% year-on-year [1] - This is the first time the company's revenue growth has fallen to single digits since its listing, indicating a slowdown in growth [1] - Despite the overall slowdown, the company experienced over 10% year-on-year revenue growth in Q3 and Q4 of 2024, attributed to a preliminary recovery in global biopharmaceutical investment [1] Revenue Breakdown - Revenue from North American clients reached 7.853 billion yuan, growing 6.11% year-on-year, accounting for 63.97% of total revenue [2] - Revenue from European clients (including the UK) was 2.272 billion yuan, with a significant increase of 23.18% year-on-year, representing 18.51% of total revenue [2] - Revenue from Chinese clients declined to 1.847 billion yuan, down 6.46% year-on-year, making up 15.05% of total revenue [2] - Revenue from other regions decreased to 304 million yuan, down 4.44% year-on-year, contributing 2.47% to total revenue [2] Strategic Initiatives - The company emphasized the importance of "AI empowerment in drug development reliability and sustainability" in its annual report [2] - In February, the company announced the acquisition of a controlling stake in Zhejiang Haixin Zhihui Technology Co., a firm focused on AI in oncology, aimed at improving patient recruitment efficiency [2]